Abstract
6669 Background: Two phase III trials in breast cancer patients treated with myelosuppressive chemotherapy showed that a single dose of pegfilgrastim provides neutrophil support comparable with that provided by an average of 11 daily injections of filgrastim. In acute myelogenous leukemia (AML) data are sparse regarding the recovery of neutrophil counts (NC) after therapy with G-CSF in chemotherapy-induced neutropenia. We compared the effects of pegfilgrastim vs. lenograstim by these patients (pts). Methods: Retrospective analysis of unselected pts with AML, 18–75 yrs of age, ECOG ≤ 2, excluding pregnancy received at least one cycle of chemotherapy. On day 1 after chemotherapy treatment either pegfilgrastim 6 mg/once per cycle or lenograstim 5 micg/kg b.w. was administered. Primary objective was the time to recovery (TTR) of NC ≥ 1.0 G/L in each treatment group after injection of G-CSF if NC nadired < 1.0 G/L temporarily. Secondary objectives were the rate of transfusion of packed red blood (PRB) and pooled platelets (PLT). Results: 29 pts, 11 m + 18 f, aged median 61.4 yrs (range: 27–75) received 47 cycles. In 5 pts (3 pts in the pegfilgrastim and 2 pts in the lenograstim group) treatment failed to elevate NC ≥ 1.0 G/L. There was a difference in the TTR of NC between pegfilgrastim 11.1 ± 6.2 days (range: 6–28) and lenograstim 13.3 ± 3.6 days (range: 6–22). Detailed characteristics are summarized in table 1. Conclusions: Both G-CSF showed adequate recovery of NC with a faster increase in those patients where pegfilgrastim was administered. Less frequently blood products were transfused in the pegfilgrastim group. According to the whole-sale pharmacy prices in Germany, G-CSF treatment per cycle for a median of 13 vials of lenograstim was about € 2,321/US $ 2,785 (range: € 1,071–3,928/US $ 1,285–4,714) compared with 1 syringe of pegfilgrastim € 1,762/US $ 2,114. No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
